Carregant...
The Immunoproteasome as a Target in Hematologic Malignancies
Suppression of proteasome function with the first-in-class small molecule inhibitor bortezomib is a rational therapeutic strategy against several hematologic malignancies, including multiple myeloma and mantle cell lymphoma. Second generation inhibitors such as carfilzomib, ixazomib, and marizomib t...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3863635/ https://ncbi.nlm.nih.gov/pubmed/22726549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminhematol.2012.04.003 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|